White House says removal of AstraZeneca vaccine from U.S. plant will not affect dose output

By Carl O’Donnell (Reuters) -A U.S. government decision to end production of AstraZeneca’s COVID-19 vaccine at Emergent BioSolutions Inc’s Baltimore manufacturing facility is not an indication of concerns about its safety or effectiveness and will not impact the output of doses, a White House official said on Monday. The U.S. Department of Health and Human Services (HHS) ordered Johnson & Johnson to take charge of production at the plant that was being used to produce both vaccines. Emergent was told to stop making AstraZeneca’s shot after the contract manufacturer made an error that ruined 15…

Read More

HEDGE accordingly